Merkel Cell Carcinoma

This is a rare type of skin cancer that starts in special cells found in the skin. These cells help us feel things. It usually happens in older people and can grow quickly.

Condition

What people with Merkel Cell Carcinoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Radiation Therapy for Merkel Cell Carcinoma?

NameHow it went

About Merkel Cell Carcinoma

What It Is

Merkel cell carcinoma (MCC) is a rare but aggressive type of skin cancer. It belongs to a group called neuroendocrine cancers, because its cells share features with nerve and hormone-producing cells. It is named after Merkel cells, which sit near nerve endings in the skin and help sense light touch, although researchers still debate exactly which cell the cancer starts from. MCC usually appears as a single firm, painless, dome-shaped lump that is pink, red or violet and grows noticeably over weeks to months. It most often shows up on sun-exposed skin, especially the head and neck, followed by the arms, legs and trunk. Because it doesn't hurt and can resemble a cyst, a bug bite or a more common skin cancer, it is easy to dismiss at first. What sets MCC apart from more common skin cancers is how quickly it can spread. It tends to travel first to nearby lymph nodes and can later reach the skin elsewhere, the lungs, liver, bones or brain. That is why finding and treating it early matters so much.

Causes & Risk Factors

Most MCC develops in one of two ways. In North America and Europe, about 4 in 5 cases are linked to the Merkel cell polyomavirus, a very common virus that most people pick up in childhood without any symptoms. Only a tiny fraction of infected people ever develop MCC, so carrying the virus is not a reason for worry or testing on its own. The remaining cases are driven by heavy sun damage to the skin's DNA; in very sunny Australia, sun-related cases are the majority. Risk rises with older age (the typical person diagnosed is in their mid-70s), fair skin, a lot of natural or artificial ultraviolet exposure (including tanning beds and PUVA, a psoriasis treatment that pairs a light-sensitizing medicine with ultraviolet A light) and a weakened immune system. People who take immune-suppressing medicines after an organ transplant, or who live with HIV or chronic lymphocytic leukemia (a slow-growing blood cancer), are at notably higher risk. Men are affected about twice as often as women. Many people with these risk factors never develop MCC, and some people who develop it have none of them.

How It's Diagnosed

MCC is diagnosed by removing all or part of the lump (a biopsy) and examining it under a microscope. Because MCC can look like several other cancers made of small round cells, including spread from a small cell lung cancer, the pathologist uses special stains that detect particular proteins on the cells to confirm the diagnosis. The report also describes the tumor's size and depth and how close it comes to the edges of the removed tissue. Once MCC is confirmed, staging shows how far it has spread, and this guides treatment. A doctor examines the whole skin and feels the lymph nodes. Imaging, usually a PET-CT scan (a combined scan that highlights areas using a lot of sugar, as cancer cells do) or computed tomography (CT) scans of the chest, abdomen and pelvis, looks for spread elsewhere. For people whose lymph nodes feel normal, a sentinel lymph node biopsy is usually done at the same time as surgery on the skin tumor. A tracer is injected near the tumor to find the first lymph node that drains it, and that node is removed and checked. This step finds hidden cancer in about a third of people whose nodes seemed normal on exam, which can change the treatment plan. The result is a stage from I to IV. Stages I and II mean the cancer is limited to the skin (stage I tumors are 2 centimeters or smaller); stage III means it has reached nearby lymph nodes; stage IV means it has spread to distant skin or organs.

Treatment Options

Because MCC is rare, care is best planned by a team experienced with it, often at a cancer center, and people may want a second opinion on the pathology and the plan. For cancer that hasn't spread beyond the skin or nearby lymph nodes, the main treatment is surgery to remove the tumor with a margin of healthy skin around it, usually followed by radiation therapy to the area. Radiation after surgery lowers the chance the cancer returns at that site. Depending on the sentinel node result, the nearby lymph nodes may be treated with radiation, surgery to remove them, or both. For people who aren't well enough for surgery, radiation alone can be used to control the tumor. Chemotherapy after surgery is generally not recommended, because it hasn't been shown to help people live longer and carries real risks for older adults. When MCC has spread widely or can't be removed, the preferred first treatment is immunotherapy with an immune checkpoint inhibitor. These drugs, usually given by infusion into a vein (IV), release a brake on the immune system so it can recognize and attack the cancer. Three are approved in the US for MCC: avelumab (Bavencio), pembrolizumab (Keytruda) and retifanlimab (Zynyz). Roughly a third to more than half of people see their tumors shrink, and for many of them the response lasts for years, although advanced MCC is not generally considered curable. Immunotherapy tends to be easier to tolerate than chemotherapy, but because it activates the immune system, it can sometimes inflame healthy organs such as the lungs, bowel, liver or hormone glands, so people are monitored with regular blood tests during treatment. For people with an organ transplant, immunotherapy can trigger rejection of the transplanted organ, and an existing autoimmune disease may flare, so the team weighs it especially carefully with them. Chemotherapy and radiation remain options when immunotherapy isn't possible or stops working. Chemotherapy often shrinks MCC, but the effect usually lasts only a few months. Radiation can relieve pain or other symptoms from a specific tumor. Clinical trials, including trials of immunotherapy before or after surgery, are an important option at every stage.

What to Expect

Outlook depends heavily on stage. In large studies, roughly two-thirds of people whose cancer was limited to the skin were alive five years later, compared with about half when nearby lymph nodes were involved and fewer than a third when it had spread to distant organs. These figures come from past records of a mostly older population, so they describe groups rather than predicting any one person's course. Treatment for early MCC usually means surgery followed by a course of radiation to the area. For advanced MCC, immunotherapy infusions are repeated on a regular schedule, with scans to check the response; how long to continue after the cancer has disappeared on scans is not yet settled. Because most people with MCC are older and many have other health conditions, overall health and personal priorities weigh heavily in choosing how intensive treatment should be. MCC comes back fairly often, and most recurrences happen within the first two to three years. Follow-up visits are typically every three to six months for the first three years, then every six months until year five, then once a year. They include a full skin and lymph node exam and, for people at higher risk, periodic scans. For people who have antibodies to the polyomavirus in their blood at diagnosis, repeating this antibody blood test can sometimes help track whether the cancer has returned. A recurrence caught early in the skin or lymph nodes can often still be treated with surgery or radiation. People who have had MCC also have a higher risk of other skin cancers, so regular self-checks of the whole skin and sun protection are worthwhile.

When to Seek Help

Have a new skin lump that is growing quickly checked soon, rather than waiting for a routine visit. It is more pressing if the lump is firm, painless and red or violet or on sun-exposed skin, or if you are older or have a weakened immune system. After treatment, contact your care team about a new lump near the scar or elsewhere in the skin, or a swollen lymph node, since these can be early signs of recurrence that are often still treatable. During immunotherapy, call your care team right away for a new or worsening cough or shortness of breath, diarrhea or severe belly pain, yellowing of the skin or eyes, severe nausea or vomiting, a new rash, or other new symptoms you can't explain. These can signal the immune system inflaming a healthy organ, and early treatment, often with steroids, matters.

Questions to Ask Your Doctor

  1. 1.What stage is my cancer, and was a sentinel lymph node biopsy or PET-CT scan part of staging?
  2. 2.Do you or this center treat many people with Merkel cell carcinoma, and would a second opinion on the pathology be worthwhile?
  3. 3.What are the goals and trade-offs of surgery, radiation and immunotherapy in my situation, and is there a clinical trial I should consider?
  4. 4.Do I have polyomavirus antibodies in my blood, and would repeating that test help with my follow-up?
  5. 5.What follow-up schedule do you recommend, and what changes should prompt me to call before my next visit?

Last reviewed • Oct 2026

Educational content, not medical advice.